ClinicalTrials.gg
Not yet recruitingNCT07807579Updated Sep 10, 2026

Impact of Dexmedetomidine Versus Propofol on Intracranial Pressure in Adult Traumatic Brain Injury Patients: Randomized Controlled Double-Blind Trial

A Phase 4 interventional study of Propofol and Dexmedetomidine in Traumatic Brain Injuries, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Assiut University · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Brain Injuries, Traumatic.

Planned enrollment
4th of 10
80 · median 76
Started
2026
with 1 other
Phase 4
3 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
Assiut University

Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 4, and was the 10th registered.

Brain Injuries, Traumatic

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

5 of the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Brain Injuries, Traumatic studies recruiting now, 124 (44%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, or all of them as a file.
02

Study summary

To investigate whether dexmedetomidine or propofol is more effective in controlling intracranial pressure (ICP) (assessed via optic nerve sheath diameter "ONSD" as a primary outcome) and which is more effective in suppressing lipid peroxidation (measured via malondialdehyde "MDA" as a secondary outcome). This double-blind randomized controlled trial aims to bridge this research gap by evaluating the biochemical neuroprotective efficacy alongside the clinical outcomes of both agents in TBI patients.

Read the detailed description

Traumatic brain injury (TBI) remains a leading cause of mortality and permanent disability worldwide, posing a major challenge in neurocritical care. The primary injury occurs at the moment of impact, resulting in immediate mechanical tissue disruption. However, the subsequent secondary brain injury develops over hours to days, driven by complex cascades of neuroinflammation, excitotoxicity, mitochondrial dysfunction, and severe oxidative stress (Werner and Engelhard, 2007).

Oxidative stress is characterized by an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defense mechanisms. The brain is particularly vulnerable to oxidative damage due to its high oxygen consumption, high lipid content (especially polyunsaturated fatty acids), and relatively low levels of antioxidant enzymes (Hall et al., 2010). During secondary injury, massive ROS production leads to lipid peroxidation, a process that degrades cell membranes and disrupts cellular integrity. Malondialdehyde (MDA) is a well-established, highly stable end-product of lipid peroxidation. Elevated systemic and cerebrospinal fluid levels of MDA serve as a reliable and sensitive biomarker for quantifying the severity of oxidative stress and predicting neurological outcomes in TBI patients (Lorente et al., 2015).

Sedation is a cornerstone in the management of mechanically ventilated TBI patients in the Intensive Care Unit (ICU). It is essential to decrease metabolic demands, facilitate mechanical ventilation, prevent spikes in intracranial pressure (ICP), and control agitation (Roberts et al., 2011).

Dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, has emerged as a promising alternative in neurointensive care. It provides "conscious sedation" without causing significant respiratory depression, allowing for easier neurological evaluation. Beyond its sedative properties, evolving preclinical and clinical evidence suggests that dexmedetomidine exerts potent neuroprotective effects (Arain and Ebert, 2002). These effects are hypothesized to be mediated through the reduction of central sympathetic outflow, attenuation of neuroinflammation, and direct modulation of oxidative stress pathways, leading to a reduction in lipid peroxidation biomarkers like MDA (Wang et al., 2019).

Propofol is a lipid-soluble anesthetic, used intravenously in the clinics for sedation in the ICU and for general anesthesia. The antioxidant properties of propofol have been attributed to the similarity of its chemical structure to known antioxidants such as butylhydroxytoluene and α-tocopherol. It has been reported that the antioxidant properties of propofol are not only inhibiting lipid peroxidation, but also scavenging the ROS that have been formed (Demiryürek et al., 1998).

03

Conditions studied

  • Traumatic Brain Injuries

Keywords

  • effect of Propofol vs Dexmedetomidine on ICP
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged between 18 and 65 years.
  2. Both genders.
  3. Moderate traumatic brain injury with Glasgow coma scale scores between 8 and 12 on admission, with no need for surgical operations.
  4. Requiring continuous sedation for more than 24 hours.

Exclusion criteria

Exclusion Criteria:

  1. History of severe hepatic or renal failure.
  2. Known to propofol or dexmedetomidine.
  3. Pre-existing severe bradycardia (heart rate less than 50 bpm) or advanced heart block.
  4. Confirmed brain death or moribund patients.
  5. Pregnancy or lactation.
  6. Preexisting neurological disease affecting GCS interpretation.
  7. General anesthesia 24 hours prior to or planned after the start of study drug infusion.
  8. Serious central nervous system pathology (acute stroke, severe dementia, uncontrolled seizures).
  9. Any patients with ocular trauma, orbital fractures, glaucoma, or history of optic nerve disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Group P : Propofol will be initiated at a continuous infusion dose of 5-50 mcg/kg/min.

    40 patients will be received Propfol at a continuous infusion dose of 5-50 mcg/kg/min.

    Drug: Propofol

  • Experimental
    Group D : Dexmedetomidine will be initiated at a continuous infusion dose of 0.2-0.7 mcg/kg/ho

    40 patients will be received Dexmedetomidine at a continuous infusion dose of 0.2-0.7 mcg/kg/hour without a loading dose to avoid hemodynamic instability.

    Drug: Dexmedetomidine

Interventions

  • evaluate intracranial pressure and serum Malondialdehyde (MDA) levels

  • evaluate intracranial pressure and serum Malondialdehyde (MDA) levels

06

What researchers measure

Primary outcomes

  1. Non-invasive intracranial pressure monitoring by optic nerve sheath diameter measurement.

    Time frame: every 6 hours for 48 hours

Secondary outcomes

  1. Serum Malondialdehyde (MDA) levels.

    Time frame: At 0 hours and after 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2027, 13 months later.

Of 25 phase 4 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 148. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07807579
Lead sponsor
Assiut University
Responsible party
Hassan Khaled ahmed gomaa (Principle Invetigator, Assiut University) — Principal investigator
First posted
Sep 8, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Hassan Khaled Ahmed
Contact
hassssan.khaled2013@gmail.com
01067319365
Mahmoud Adel Ali
Contact
dr_mahmoudfaisal@aun.edu.eg
01004391577

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propofol · Dexmedetomidine

Start the discussion